Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

Dow Jones11-26 23:12

10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

November 26, 2024 10:12 ET (15:12 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486002310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486002310","market":"sg","top_or_hot":-1,"title":"Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones &amp; Co. owns Factiva. (chris.wack@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 10:12 ET (15:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 23:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTX","symbol_name":"Poseida Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486002310","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486002310","pubTimestamp":1732633920,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSTX":"Poseida Therapeutics, Inc.","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics","03165":"华夏欧优股对冲","RHHBY":"罗氏控股"},"translate_title":"热门话题：罗氏将以高达15亿美元收购Poseida Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PSTX":1,"RHHBY":0.9,"03165":0.6},"content_text":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 10:12 ET (15:12 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486002310"}